MX2022013927A - Composiciones y metodos para tratar la epilepsia. - Google Patents

Composiciones y metodos para tratar la epilepsia.

Info

Publication number
MX2022013927A
MX2022013927A MX2022013927A MX2022013927A MX2022013927A MX 2022013927 A MX2022013927 A MX 2022013927A MX 2022013927 A MX2022013927 A MX 2022013927A MX 2022013927 A MX2022013927 A MX 2022013927A MX 2022013927 A MX2022013927 A MX 2022013927A
Authority
MX
Mexico
Prior art keywords
methods
treating epilepsy
compositions
administering
inhibitor
Prior art date
Application number
MX2022013927A
Other languages
English (en)
Inventor
Ted Yednock
Sethu Sankaranarayanan
Jeanne T Paz
Original Assignee
The J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Glads
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Glads filed Critical The J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Glads
Publication of MX2022013927A publication Critical patent/MX2022013927A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2857—Seizure disorders; Epilepsy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción se refiere, en términos generales, a métodos para prevenir, reducir el riesgo de desarrollar o tratar la epilepsia, que comprenden administrar a un sujeto un inhibidor de la vía clásica del complemento.
MX2022013927A 2020-05-05 2021-05-05 Composiciones y metodos para tratar la epilepsia. MX2022013927A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063020245P 2020-05-05 2020-05-05
PCT/US2021/030930 WO2021242493A2 (en) 2020-05-05 2021-05-05 Compositions and methods for treating epilepsy

Publications (1)

Publication Number Publication Date
MX2022013927A true MX2022013927A (es) 2022-11-30

Family

ID=78745740

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013927A MX2022013927A (es) 2020-05-05 2021-05-05 Composiciones y metodos para tratar la epilepsia.

Country Status (8)

Country Link
US (1) US20240034775A1 (es)
EP (1) EP4146276A4 (es)
JP (1) JP2023524819A (es)
CN (1) CN115996752A (es)
AU (1) AU2021278819A1 (es)
CA (1) CA3177879A1 (es)
MX (1) MX2022013927A (es)
WO (1) WO2021242493A2 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY175896A (en) * 2013-07-09 2020-07-14 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
BR112017009297B1 (pt) * 2014-11-05 2024-02-15 Annexon, Inc Anticorpos antifator de complemento c1q humanizados, composição farmacêutica e kit compreendendo os mesmos, uso terapêutico destes,polinucleotídeo isolado, célula hospedeira isolada, bem como métodos in vitro para detectar sinapses
WO2016081643A1 (en) * 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
EP3454901A4 (en) * 2016-05-09 2020-07-29 Annexon, Inc. COMPOSITIONS AND METHODS FOR TREATING PROGRESSIVE SPINAL AMYOTROPHY
AU2017299579A1 (en) * 2016-07-19 2019-01-24 Annexon, Inc. Compositions and methods for treating frontotemporal dementia

Also Published As

Publication number Publication date
EP4146276A2 (en) 2023-03-15
WO2021242493A2 (en) 2021-12-02
CN115996752A (zh) 2023-04-21
JP2023524819A (ja) 2023-06-13
WO2021242493A3 (en) 2022-06-09
US20240034775A1 (en) 2024-02-01
CA3177879A1 (en) 2021-12-02
EP4146276A4 (en) 2024-08-14
AU2021278819A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
MY196582A (en) PD-1/PD-L1 Inhibitors
MX2021014350A (es) Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos.
MX2022007968A (es) Dosificacion de gamma-hidroxibutirato (ghb).
MX2022001004A (es) Inhibidores de enzimas.
PH12020551995A1 (en) Modulator of apol1 expression
NI202100018A (es) Moduladores de la expresión de pnpla3
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
MX2024000271A (es) Inhibidor de shp2 y uso del mismo.
MX2021007503A (es) Moduladores de la expresion de hsd17b13.
PH12019502174A1 (en) Modulators of pcsk9 expression
WO2019157495A3 (en) Methods for preventing and/or treating bone loss conditions by modulating irisin
MX2021013901A (es) Composiciones y métodos para el tratamiento del cáncer.
MX2024000805A (es) Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerotica.
MX2022000812A (es) Metodos de tratamiento de hiperplasia suprarrenal congenita.
WO2023108110A3 (en) Combination therapy for treating abnormal cell growth
MX2024001774A (es) Compuesto inductor de la degradacion de plk1 novedoso.
MX2022010960A (es) Métodos y composiciones para tratar el trastorno por uso de cannabis y mitigar la abstinencia de cannabinoides.
MX2022000811A (es) Inhibidores de enzimas.
MX2022000545A (es) Inhibidores de enzimas.
ZA202106519B (en) Caspase inhibitors and methods of use thereof
MX2022013927A (es) Composiciones y metodos para tratar la epilepsia.
MX2022008532A (es) Inhibidores de hidrocarburo de arilo (ahr) y usos de estos.
WO2020086954A3 (en) Treatments for charcot-marie-tooth disease
MX2022000783A (es) Inhibidores de la ferroportina para el uso en la prevencion y el tratamiento de lesiones renales.
MX2022000801A (es) Composicion y metodo para prevenir, aliviar o tratar lesion del higado.